Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review.

Abstract

INTRODUCTION:

The efficacy of once-weekly (O.W.) semaglutide for the treatment of type 2 diabetes mellitus (T2DM) has been demonstrated in clinical trials. The aim of this systematic literature review was to summarize real-world evidence for O.W. semaglutide.

METHODS:

A comprehensive search of PubMed, Web of Science, Embase, and Scilit databases was performed from January 2017 to June 2022 to identify eligible real-world studies examining O.W. semaglutide in T2DM.

RESULTS:

Thirty-one records (18 full-text and 13 abstracts) were identified. The general characteristics of studies and included patients were summarized. Changes in glycated hemoglobin (HbA1c) and body weight were analyzed across studies and according to patient characteristics: baseline HbA1c/weight level, GLP-1 RA-naïve/ GLP-1RA-experienced. The effectiveness of O.W. semaglutide compared with dulaglutide, and the dose of O.W. semaglutide in the real world were also summarized.

CONCLUSIONS:

This systematic literature review provided complementary evidence to findings from the clinical trials and provided a more comprehensive picture of the use of O.W. semaglutide in routine clinical practice. Results of the review suggested that O.W. semaglutide therapy was associated with improving glycemic control and weight loss in both T2DM patients naïve to GLP-1RA and those previously treated with other GLP-1RA in routine clinical practice.

PROSPERO REGISTRATION:

CRD42022306164.

• Authors: Zhen Ruan, Yixuan Jiang, Honghao Shi, Ruxu Jia, Carolina Oi Lam Ung, Hao Hu
• Journal: Expert review of clinical pharmacology (Expert Rev Clin Pharmacol) Vol. 16 Issue 2 Pg. 161-176 (Feb 2023) ISSN: 1751-2441 [Electronic] England
• PMID: 36706368 (Publication Type: Systematic Review)

Chemical References

• semaglutide
• Hypoglycemic Agents
• Glycated Hemoglobin
• Glucagon-Like Peptides
• Glucagon-Like Peptide 1

Topics

• Humans
• Diabetes Mellitus, Type 2 (drug therapy)
• Hypoglycemic Agents
• Glycated Hemoglobin
• Drug Administration Schedule
• Glucagon-Like Peptides
• Body Weight
• Glucagon-Like Peptide 1 (therapeutic use)
• Treatment Outcome